Ingestible device with expandable enclosure

Patent metadata

Field	Value
Publication number	US-12128133-B2
Application number	US-201916579112-A
Country	US
Kind code	B2
Filing date	Sep 23, 2019
Priority date	Sep 25, 2018
Publication date	Oct 29, 2024
Grant date	Oct 29, 2024

Abstract

An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

First claim

The invention claimed is:

1. A method for delivering a therapeutic agent into a small intestine of a subject using an ingestible device, the method comprising:
administering the ingestible device to the subject by ingestion and thereby initiating transport of the device to the small intestine, wherein the ingestible device comprises an outer shell that contains (i) a shaped composition comprising the therapeutic agent and (ii) a delivery mechanism, the delivery mechanism comprising an expandable enclosure including a head region, a predetermined retention region, and a tail region, wherein the expandable enclosure is structured such that, when expanded, a dimension of the predetermined retention region of the expanded expandable enclosure is less than a dimension of the head region of the expanded expandable enclosure and less than a dimension of the tail region of the expanded expandable enclosure, wherein the delivery mechanism is structured to expand the expandable enclosure responsive to a condition in the small intestine;
wherein the outer shell degrades in situ in the small intestine to expose the delivery mechanism, wherein responsive to said condition in the small intestine, the delivery mechanism expands the expandable enclosure such that the head region and the tail region of the expandable enclosure expand against a wall of the small intestine, wherein a dimension of the predetermined retention region of the expanded expandable enclosure is less than a dimension of the head region of the expanded expandable enclosure and less than a dimension of the tail region of the expanded expandable enclosure, to define a protective volume bounded by the expanded expandable enclosure and the wall of the small intestine, wherein the shaped composition is disposed within the protective volume and exposed to the small intestine; and
wherein exposure of the shaped composition to the small intestine initiates degradation of the shaped composition that releases the therapeutic agent from the shaped composition into the protective volume for transport through the wall of the small intestine.

2. The method of claim 1 , wherein the condition in the small intestine is a pH in the small intestine.

3. The method of claim 1 , wherein the shaped composition comprises a coating which is structured to degrade in the small intestine after a designed period of time, such that the therapeutic agent is released into the protective volume after the designed period of time.

4. The method of claim 3 , wherein the designed period of time is greater than a designed time for expansion of the head region and the tail region of the expandable enclosure.

5. The method of claim 1 , wherein the shaped composition further comprises a delivery enhancing agent selected to enhance transport of the therapeutic agent across the wall of the small intestine, wherein exposure of the shaped composition to the small intestine initiates degradation of the shaped composition that releases the delivery enhancing agent from the shaped composition into the protective volume to enhance transport of the therapeutic agent through the wall of the small intestine, and wherein the initiation of the release of the therapeutic agent is subsequent to the initiation of the release of the delivery enhancing agent.

6. The method of claim 1 , wherein the delivery mechanism expands the head region and the tail region by a chemical reaction.

7. The method of claim 1 , wherein the shaped composition is a first shaped composition of a plurality of shaped compositions disposed in the ingestible device, and a mass of the therapeutic agent in the first shaped composition is a first mass.

8. The method of claim 7 , wherein at least a second one of the plurality of shaped compositions comprises a different mass of the therapeutic agent than the first mass.

9. The method of claim 7 , wherein the therapeutic agent is a first therapeutic agent and the plurality of shaped compositions comprises at least the first therapeutic agent and a second therapeutic agent different than the first therapeutic agent.

10. The method of claim 7 , wherein the plurality of shaped compositions comprises a second shaped composition comprising the therapeutic agent, the first shaped composition is designed to release the therapeutic agent after a first time period subsequent to the exposure to the small intestine, the second shaped composition is designed to release the therapeutic agent after a second time period subsequent to the exposure to the small intestine, and the second time period is designed to be longer than the first time period.

11. The method of claim 7 , wherein the plurality of shaped compositions comprises at least a first delivery enhancing agent and a second delivery enhancing agent different than the first delivery enhancing agent, wherein the first and second delivery enhancing agents are selected to enhance transport of the therapeutic agent across the wall of the small intestine.

12. The method of claim 1 , wherein the therapeutic agent comprises an immunoglobulin.

13. The method of claim 12 , wherein the immunoglobulin comprises immunoglobulin G.

14. The method of claim 12 , wherein the immunoglobulin comprises a TNF-alpha antibody.

15. The method of claim 12 , wherein the immunoglobulin comprises an antibody to an interleukin in an IL-17 family of interleukins.

16. The method of claim 1 , wherein the shaped composition further comprises a delivery enhancing agent selected to enhance transport of the therapeutic agent across the wall of the small intestine.

17. The method of claim 16 , wherein the delivery enhancing agent comprises a protease inhibitor.

18. The method of claim 16 , wherein the delivery enhancing agent comprises a permeability enhancer which enhances a permeability of a wall of the small intestine to the therapeutic agent.

19. The method of claim 18 , wherein the delivery enhancing agent fluidizes a plasma membrane of cells in an epithelial layer of the small intestine.

20. The method of claim 19 , wherein the permeability enhancer comprises a medium chain fatty acid (MCFA)-based sodium caprate, sodium caprylate, sodium caprylate derivative, acyl carnitines or ethylenediaminetetraacetic acid (EDTA).

21. The method of claim 18 , wherein the delivery enhancing agent induces sloughing of cells from an epithelial layer of an intestinal wall.

Assignees

• Rani Therapeutics Llc

Inventors

• Imran Mir A

Classifications

• C07K16/241

  Tumor Necrosis Factors · CPC title

• A61M25/10

  Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00}) · CPC title

• C07K16/244

  Interleukins [IL] · CPC title

• A61M2025/105

  having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes · CPC title

• C07K16/283

  against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851) · CPC title